4 hours ago
3
ARTICLE AD BOX
NEW DELHI/HYDERABAD: India's generic companies are apt to proceed successful business-as-usual mode arsenic US President Donald Trump's 100% levy connected pharmaceuticals is targeted astatine branded and patented medicines, but it whitethorn besides punctual immoderate of them to rethink their playbook.Industry experts told TOI that the country's largest drugmaker Sun Pharma could look headwinds arsenic its cause income successful US totalled $1.1 cardinal successful FY25 (in which patented drugs person a important portion), which was astir 17% of its full revenue. Analysts added that branded biosimilars manufactured by companies, including Biocon, whitethorn beryllium affected.Companies with manufacturing bases successful US - including Sun Pharma, Dr Reddy's and Cipla - could cushion the stroke by shifting accumulation of higher-value specialty and niche drugs from India to the American facilities, said experts.
Over time, the determination could thrust companies to diversify export markets, recalibrate planetary strategies, displacement to declaration manufacturing successful the US and acceptable up manufacturing bases determination to safeguard entree to the world's astir lucrative market."At this point, we bash not spot an impact," Dr Reddy's co-chairman & MD G V Prasad said, adding, the institution besides does not spot expanding its manufacturing footprint successful the US immediately.
"Domestic companies are examining each options to mitigate risk, ranging from mounting up manufacturing facilities successful the US to shifting accumulation of high-value specialty drugs, niche therapies and peptides to existing plants," an manufacture adept said. India's pharma exports to the US were adjacent to $10 cardinal past twelvemonth and it serviced astir 35% of US prescriptions with affordable generics."India plays a captious relation successful US healthcare by ensuring a dependable proviso of affordable medicines.
A bulk of life-saving cardiac, diabetes and chronic medicines are supplied from India," said Indian Pharmaceutical Alliance caput wide Sudarshan Jain. Deepak Jotwani, VP & assemblage head, firm ratings, Icra added, "Overall, this determination by the US underscores the request for Indian pharma companies to diversify markets and innovate successful analyzable generics and biosimilars to enactment resilient successful a changing planetary commercialized landscape.
"Pharmexcil president Namit Joshi said astir ample Indian companies already run manufacturing oregon repackaging units successful US and are exploring further acquisitions. "India volition request to reenforce its cost-efficiency vantage successful bulk drugs and APIs, an country wherever the US is apt to favour India implicit different suppliers, and simultaneously put successful next-generation opportunities, specified arsenic analyzable generics, peptides and biosimilars.
" The pharma assemblage is awaiting much clarity connected the announcement arsenic it did not specify whether speciality drugs, niche oregon analyzable generic drugs are nether its ambit. However, a fewer experts said determination was uncertainty implicit the explanation of "branded" drugs. "If we instrumentality the presumption branded and patented products astatine look value, Granules does not autumn into either category," Granules India ED Priyanka Chigurupati said.
